A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
A phase 3 trial of Elranatamab, Daratumumab, Lenalidomide in multiple myeloma, run by Pfizer, now recruiting.
Overview
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant is a phase 3 interventional study registered as NCT05623020 by Pfizer, with 1116 participants planned, started 2022-11-10 and due to reach its primary completion in 2030-10-18. Interventions recorded: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Elranatamab, Daratumumab, Dexamethasone, Pfizer (incl. Seagen).
- TrialStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Shares Elranatamab, Lenalidomide, Pfizer (incl. Seagen), Multiple myeloma.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elranatamab, Bortezomib, Dexamethasone, Pfizer (incl. Seagen).
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.